Business Description
Nymox Pharmaceutical Corp
NAICS : 325412
SIC : 2835
ISIN : BSP733981026
Description
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.36 | |||||
| Equity-to-Asset | -5.06 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 15.4 | |||||
| 3-Year EPS without NRI Growth Rate | 16 | |||||
| 3-Year FCF Growth Rate | 31.4 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 81.54 | |||||
| 9-Day RSI | 68.43 | |||||
| 14-Day RSI | 60.86 | |||||
| 6-1 Month Momentum % | -33.31 | |||||
| 12-1 Month Momentum % | -82.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.16 | |||||
| Quick Ratio | 0.16 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.3 | |||||
| Shareholder Yield % | -1.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROA % | -1173.88 | |||||
| ROIC % | -1889.77 | |||||
| ROC (Joel Greenblatt) % | -12334.27 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| EV-to-EBIT | -1.06 | |||||
| EV-to-EBITDA | -1.08 | |||||
| EV-to-FCF | -1.18 | |||||
| Earnings Yield (Greenblatt) % | -94.34 | |||||
| FCF Yield % | -28.94 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:NYMXF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nymox Pharmaceutical Corp Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.1 | ||
| Beta | 24.73 | ||
| Volatility % | 17050.22 | ||
| 14-Day RSI | 60.86 | ||
| 14-Day ATR ($) | 0.044467 | ||
| 20-Day SMA ($) | 0.082655 | ||
| 12-1 Month Momentum % | -82.8 | ||
| 52-Week Range ($) | 0.0001 - 1.4 | ||
| Shares Outstanding (Mil) | 93.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nymox Pharmaceutical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nymox Pharmaceutical Corp Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nymox Pharmaceutical Corp Frequently Asked Questions
What is Nymox Pharmaceutical Corp(NYMXF)'s stock price today?
The current price of NYMXF is $0.15. The 52 week high of NYMXF is $1.40 and 52 week low is $0.00.
When is next earnings date of Nymox Pharmaceutical Corp(NYMXF)?
The next earnings date of Nymox Pharmaceutical Corp(NYMXF) is 2024-12-03 Est..
Does Nymox Pharmaceutical Corp(NYMXF) pay dividends? If so, how much?
Nymox Pharmaceutical Corp(NYMXF) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers